A study to assess safety and tolerability of oral AZD3241 in patients with Parkinson's disease

Study identifier:D0490C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients with Parkinson's Disease

Medical condition

Parkinson's disease

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD3241 300 mg BID, AZD3241 600 mg BID, Placebo

Sex

All

Actual Enrollment

51

Study type

Interventional

Age

30 Years - 80 Years

Date

Study Start Date: 01 Oct 2012
Primary Completion Date: 01 Jun 2013
Study Completion Date: 01 Jun 2013

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria